Pricing

Five things for pharma marketers to know: Tuesday, September 1

Five things for pharma marketers to know: Tuesday, September 1

By

Amgen gives hefty discount to Repatha in Europe; Valeant partners with AstraZeneca on controversial psoriasis drug; Pfizer now offers single packages of Viagra

Five things for pharma marketers to know: Wednesday, August 26

Five things for pharma marketers to know: Wednesday, August 26

By

Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review

Five things for pharma marketers to know: Tuesday, August 11

Five things for pharma marketers to know: Tuesday, August 11

By

"Me-too" drugs may help lower costs; start-ups send doctors to your home; the FDA is likely to appeal the Amarin ruling

Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

By

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe

Five things for pharma marketers to know: Friday, July 24

Five things for pharma marketers to know: Friday, July 24

By

UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth

Five things for pharma marketers to know: Tuesday, July 21

Five things for pharma marketers to know: Tuesday, July 21

By

Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter

Novartis bets on demand for new heart-failure drug Entresto

Novartis bets on demand for new heart-failure drug Entresto

By

The FDA approval this week of a new heart-failure drug is expected to spur interest among cardiologists seeking new ways to keep patients with heart failure out of the hospital.

Five things for pharma marketers to know: Tuesday, July 7

Five things for pharma marketers to know: Tuesday, July 7

By

Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher

Five things for pharma marketers to know: Thursday, July 2

Five things for pharma marketers to know: Thursday, July 2

By

Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs

BMS combo would gain heft in melanoma space, say analysts

BMS combo would gain heft in melanoma space, say analysts

By

The promise of an Opdivo/Yervoy combination, now awaiting FDA approval, has more to do with payer strategy than efficacy, analysts say.

Clinton tells pharma to explain drug prices

Clinton tells pharma to explain drug prices

Speakers at Klick Health's event criticized, lauded the role of technology in healthcare.

Five things for pharma marketers to know: Tuesday, June 16

Five things for pharma marketers to know: Tuesday, June 16

By

Novo Nordisk replaces Sanofi as the top marketer of metabolic drugs; Actavis changed its name to Allergan; access to Medicare Part D has not reduced overall Medicare costs

Study: 10 medications will cost US $50 billion over 10 years

Study: 10 medications will cost US $50 billion over 10 years

By

An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.

Study: Patients with marketplace health plans spend less on medications

Study: Patients with marketplace health plans spend less on medications

By

Employer-insured enrollees spend more on prescriptions than health-insurance exchange enrollees, but the groups spend the same amount of money when it comes to specialty medications, a study shows.

Five things for pharma marketers to know: Thursday, May 28

Five things for pharma marketers to know: Thursday, May 28

By

The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate

Express Scripts wants cancer drugs to prove value

Express Scripts wants cancer drugs to prove value

By

The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.

Inhaled insulin stymied by drive for value

Inhaled insulin stymied by drive for value

By

Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.

Five things for pharma marketers to know: Thursday, May 7

Five things for pharma marketers to know: Thursday, May 7

By

A court halted the launch of Sandoz's biosimilar; GSK said it is concerned about Advair competition in the US; an FDA panel is expected to vote on a female sexual disorder drug

Five things for pharma marketers to know: Wednesday, May 6

Five things for pharma marketers to know: Wednesday, May 6

By

Amgen raises price of Enbrel by 10%; pharma companies appear to raise diabetes drug prices in tandem; Alexion agrees to buy rare-disease drugmaker for $8.4 billion

Five things for pharma marketers to know: Tuesday, May 5

Five things for pharma marketers to know: Tuesday, May 5

By

Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman

Five things for pharma marketers to know: Tuesday, April 28

Five things for pharma marketers to know: Tuesday, April 28

By

Merck said Januvia is not linked to higher heart-failure risk; Biogen plans to spend $2.5 billion on Alzheimer's disease; Mylan rejected Teva's bid

Five things for pharma marketers to know: Tuesday, April 21

Five things for pharma marketers to know: Tuesday, April 21

By

Teva proposes acquisition of Mylan; start-up offers BRCA testing for $249; Botox receives another label expansion

US drug spending shows reliance on specialty Rx

US drug spending shows reliance on specialty Rx

By

Americans spent 13.1% more on prescription medications in 2014 than they did in 2013, but recent launches indicate competition in the specialty drug space is going to heat up.

High cancer costs associated with better outcomes

High cancer costs associated with better outcomes

By

Researchers say countries that spend the most on cancer care have better outcomes, but the explanation behind improved mortality is not clear.

FDA will study the impact prices have on Rx purchases

The study will include DTC and DTP advertising.

ASCO wants to talk value when talking cancer

ASCO wants to talk value when talking cancer

By

An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

By

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

Five things for pharma marketers to know: Tuesday, March 17

Five things for pharma marketers to know: Tuesday, March 17

By

Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing

Five things for pharma marketers to know: Thursday, March 12

Five things for pharma marketers to know: Thursday, March 12

By

The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.

Report: US drug spending jumped 13% in 2014

Report: US drug spending jumped 13% in 2014

By

PBM Express Scripts said last year's trends reflect a major shift in how the pharmaceutical industry does business and that generics are not the bargain they once were.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.